The Impact of Focality and Centricity on VIN Disease Progression in HIV+ and HIV- patients: A 10-Year Retrospective Study

By

Ayakannu T[1, 2], Murugesu S[3], Taylor AH[4], Sokhal P[5], Limandhee R[5],

Wilhelm-Benartzi CSM[5], D Lyons[6], *Chatterjee J[1,2,5]

[1]Department of Gynaecology Oncology, Royal Surrey County Hospital, NHS Foundation Trust, Egerton Road, Guildford, GU2 7XX, UK

[2]Faculty of Health and Medical Sciences, Department of Clinical and Experimental Medicine, Leggett Building, University of Surrey, Guildford, Surrey, GU2 7XX, UK

[3] Department of Obstetrics and Gynaecology, Hillingdon Hospital, Uxbridge, UB8 3NN, UK

[4]Department of Molecular and Cellular Biology, University of Leicester, Leicester, LE1 7RH, UK

[5]Department of Cancer and Surgery, Imperial College London, Institute of Reproductive and Development Biology, Du Cane Road, London, W12 ONN, UK.

[6]Department of Obstetrics and Gynaecology, St Mary's Hospital, Paddington, London, W2 1NY, UK.

*To whom correspondence should be addressed

Mr Jayanta Chatterjee

Department of Gynaecology Oncology, Royal Surrey County Hospital, NHS Foundation Trust, Egerton Road, Guildford, GU2 7XX, UK

Tel: +44 (0) 1483 571 122

Fax: +44 (0) 1483 402 742

Email: jayanta.chatterjee1@nhs.net

Number of words: 2384 Number of Tables: 2 Number of figures: 3

Abstract

Background: The impact of lesion focality and centricity in relation to patient outcome and disease recurrence of vulvar intraepithelial neoplasia (VIN) is an understudied area of research, especially in immunocompromised women. The prevalence and incidence of VIN have increased steadily since the 1980s, because of the co-existence of human papilloma virus (HPV) and human immunodeficiency virus (HIV). In this study, we have retrospectively examined the records of VIN patients (both HIV+ and HIV-) to determine the effect of lesion focality and centricity with respect to the risk of and interval to disease recurrence.

Material & Methods: All women diagnosed with VIN and managed between January 2002 and December 2011 were included and followed up until December 2017. They were identified by searching histopathology and diagnosis records in hospital colposcopy databases. Symptoms at the time of presentation, subsequent treatment and outcomes were collated, including the influences of multifocality and multicentricity on time to disease recurrence.

Results: A total of 90 women with were VIN identified, from which 78 records were recovered indicating focality and centricity. 15 patients were HIV+ and 75 were HIV-. HIV+ women presented with fewer symptoms than the HIV- women. Multicentricity caused a more rapid recurrence of disease than unicentricity ($p=0.006$), whereas multifocality increased the risk of recurrence more than unifocality ($p<0.0001$). Viral load in the HIV+ patients was not associated with time to disease recurrence but the number of CD4+ lymphocytes present in HIV+ patients was.

Conclusion: Both focality and centricity have an effect on interval to recurrence and final patient outcome, with multifocal disease having a poorer prognosis. Centricity and focality should be recorded at the time of diagnosis and act as a concern for disease recurrence. HIV+ VIN patients with multifocal disease and/or known immunosuppression (low CD4+ lymphocyte counts) should be regarded as 'high-risk' patients and treated accordingly.

Keywords: Vulva, intraepithelial neoplasms, focality, centricity, HIV, disease recurrence, CD4

Funding statement: The work presented here was not funded by any charity or organisation.

Disclosure statement: *The authors report no conflicts of interest.*

Running title: Lesion focality/centricity effect on risk of VIN recurrence

Author's contributions: T. Ayakannu was responsible for designing and drafting the original manuscript and revision for important intellectual content. J. Chatterjee and D. Lyons conceptualized the original study, were involved in manuscript revision, supervised data collection and also for providing important intellectual input into the work. They take responsibility for the conduct of the study. S. Murugesu, P. Sokhal and R. Limandhee were responsible for collection of data and presenting some of the work at national and international conferences. A.H. Taylor aided in the re-analysis of some of the data and CSM Wilhelm-Benartzi was involved in the statistical analysis for the paper. All authors contributed to the design of the paper and have approved the final draft.

Introduction

Vulval intraepithelial neoplasia (VIN) is a condition in which changes occur in the skin covering the vulva of female external genitalia. It can change from a condition that is relatively benign (VIN1) into one that has the potential to become invasive (VIN3), affecting all surface tissues of the pelvic floor (mons into perianal region). In 1986, the International Society for the Study of Vulvovaginal Disease (ISSVD) devised a classification system for VIN, which was updated in 2004 and remains the most commonly used system in literature [1]. Pre-invasive abnormalities in vulval tissue are categorised as VIN 1–3, depending on the level of dysplasia present, which is similar to the current grading of cervical intraepithelial neoplasia (CIN), a related and often coincident (multicentric) finding during clinical examination and diagnosis. It is widely believed that VIN 1 has a low malignant potential and is not a precursor of VIN 2 or 3, which have high malignant potential, often presenting with or developing into invasive squamous cell carcinoma (SCC).

Since the 1980s, the incidence of VIN as a disease entity has been reported to have increased in several countries and in particular within the younger female population [2]. Even so, VIN remains a relatively uncommon condition, with an unclear aetiology. Younger women tend to have the 'usual-type' VIN that is characterized by previous or existing exposure to human papillomavirus (HPV), whereas older women tend to have the 'unusual-type' VIN (also called differentiated VIN), which is not related to HPV exposure, but is related to chronic dermatological conditions, in particular vulval lichen sclerosis [3]. The symptoms reported by patients with VIN are itching, burning, dyspareunia and the appearance of leucoplakic patches in any part of the vulva. Often patients are asymptomatic as well and suspected VIN is observed during colposcopy for cervical abnormality or during general gynaecological examination. Emerging evidence suggest that the type of VIN and recurrence of disease may be related to the presence of viruses other than HPV, such as human

immunodeficiency virus (HIV) and in immunocompromised patients, suggesting that immunomodulation may have a prognostic effect in some, but not all, forms of VIN [4].

Due to the multi-factorial and heterogeneous nature of VIN, there is no single characteristic or pathognomonic feature that can facilitate the diagnosis of VIN. If VIN is suspected, visual inspection of the vulva and surrounding tissues (cervix, vagina, perineum, anus, rectum and gluteal folds) with vulvoscopy guiding the collection of vulval biopsy and confirmation of the disease is made by histological examination. VIN in more than one part of the vulval tissue is defined as ***multifocal***, whilst the presence of lesions in more than one genital site is defined as being ***multicentric*** *disease.* The importance of vulvoscopy is based on the observed prevalence of microscopic abnormalities adjacent to the gross lesion that becomes pronounced with the uptake of acetic acid. In some series, additional areas of VIN have been found in 80% of the areas adjacent to the primary lesion [5]. This high rate of concurrent disease is most characteristic of younger women.

There are numerous standard treatments for VIN and for the prevention of VIN2/3 progressing to vulval cancer [6-9]. The gold standard treatment for high-grade vulval intraepithelial lesions is surgery, either localized or radical excision or laser ablation [10]. Alternatively, immune modulators such as imiquimod [11-13] can be used as adjunctive therapy, although the efficacy and side effects of this combined treatment remain undetermined.

The primary aim of this study was to determine the impact of lesion focality and centricity at VIN presentation in relation to patient outcome and disease recurrence. In particular, the effectiveness of different treatment modalities on disease free duration, disease recurrence, and failure rates, based on focality and centricity of the disease at presentation was

assessed. In addition, this study also assesses how VIN presentation and outcomes varied with immune status, specifically HIV status was used to interrogate this.

Methods

This retrospective cohort study was conducted over 10 years in a tertiary University Hospital setting (the West London Cancer Centre, Imperial College Hospitals NHS Trust) by examining the records of women at Hammersmith and St Mary's Hospitals between January 2002 and December 2011. The women were identified through a search of histopathology and colposcopy databases. All women diagnosed with VIN and managed within this period were included; women were suitable for inclusion irrespective of VIN type or grade of the disease. A search by histological diagnosis of VIN was performed and hospital numbers obtained. St. Mary's Hospital data was collected from the colposcopy database 'Excelicare' and pathology database 'Telepath'. Hammersmith Hospital data was obtained from patients' paper medical and histopathology records.

Symptoms at the time of presentation were collated, together with patient age at the time of initial presentation, smoking status, HPV and HIV status, CD4+ lymphocyte count and viral load (only in the HIV+ patients), and if the lesions present were unifocal/multifocal and unicentric/multicentric. Viral load was determined using an immunoassay (IA) that simultaneously detects both antibody to human immunodeficiency virus (HIV) and HIV p24 antigen (Architect HIV Ag/Ab Combo) and confirmation was made using LIAISON® XL MUREX HIV Ab/Ag HT. CD4 positivity was determined using fluorescence activated cell sorting on a BD FACS Canto analyser (BD Biosciences, San Jose, CA). The initial, subsequent and adjunctive treatment regimen(s), whether the patient remained disease free or if disease recurred (until December 2017), the time from treatment to recurrence and final patient outcome(s) were all recorded.

Univariate analysis using permutation χ^2 tests (10 000 permutations; R version 2.10) were used to evaluate statistical significance with respect to the effect of treatment on VIN recurrence and patient outcomes, whilst Fisher's exact test and linear regression analysis (GraphPad Prism version 7.00 for Windows, GraphPad Software, La Jolla California USA, www.graphpad.com) were used to determine the influences of multifocality and multicentricity on time to disease recurrence after treatment. Demographic data were analyzed with unpaired Student's t-test with Welch's correction for non-uniform variances (Prism version 7.00).

Results

A total of 90 women with a diagnosis of VIN were identified during the 10 years study period. The mean (± SD) age at presentation was 44.8 ± 15.1 years (range 20-86) for the patient cohort. Of these, 15 patients (16.6%) were HIV+ and 75 (83.3%) were HIV-. The ages of these two groups at presentation were not significantly different (40.4 ± 8.8 years (range 27-57) and 45.7 ± 15.9 (range 20-86) respectively, (p=0.313).

At the time of presentation, 61% of the HIV- patients were smokers whilst only 23% of the HIV+ patients were smokers – probably should put total numbers in brackets, alongside percentages. Although those who smoked in the HIV+ group smoked less than 20 cigarettes/day and some of the HIV- group - insert number in brackets(6%) smoked more than 20 cigarettes/day, analysis showed that smoking was not a confounding factor in later analyses for either group.

The HIV+ subgroup presented with fewer symptoms than the HIV- group, and more patients were asymptomatic (Figure 1a). The presence of a lesion, pruritus, pain or a combination of

these symptoms were similar in both groups, although 'soreness' was only reported in the HIV- group. The type of lesion present and initially diagnosed was similar in both groups, with 76% of the HIV- group and 93% of the HIV+ group, respectively presenting with VIN3 or invasive disease (Figure 1b). Furthermore, 60% of HIV+ patients had a coincidental diagnosis of cervical intraepithelial neoplasia (CIN) and or vaginal intraepithelial neoplasia (VAIN), in contrast to only 28% of HIV- patients (Figure 1c). The majority HIV+ patients (87%) had a previous diagnosis of CIN/VAIN, compared to only 48% of the HIV- patients (Figure 1c). – insert numbers as well as percentagesThis data was not statistically significantly different (p=0.56; Fisher's exact test).

Histological diagnosis confirmed the presence of VIN in all patients, with 24 women (37%) having unifocal disease and 54 (69%) having multifocal disease. Furthermore, 30 patients (38%) had unicentric disease and 48 (61%) had multicentric disease (Table 1) and in 12 cases (15%), the number and positions of lesions were not recorded. Since multiple combinations are possible at diagnosis, these possible combinations are presented together in Table 1.

There were nine different management plans put in place at initial presentation (Table 2) and none of the patients were treated with cidofovir or photodynamic therapy; 39 patients were managed conservatively. Of this group, one went on to have examination under anaesthesia (EUA) and one went on to develop invasive disease. Laser treatment as initial treatment was used on 23 patients and of these, 7 had recurrent disease within a year and 15 within 2 years. Diathermy ablation was used to treat 12 patients and 3 patients had diathermy excision. Only one patient in our cohort who was treated with imiquimod alone, relapsed and had recurrence of disease – could define time in this as only one patient. In this case, the patient did not require any further treatment (Table 2). One patient had radiotherapy (following diagnosis of invasive cancer), one referred to a cancer centre and 1

had a vulvectomy. At the time of writing, only 3 (20%) HIV+ patients and 30 (38.5%) HIV- patients are disease free, whilst 12 patients (13.3%) have been lost to follow-up. One patient died of Hodgkin's lymphoma and 3 died of causes that were not recorded in their notes and two developed invasive vulval carcinoma (Table 2). Of the 78 patients that had detailed notes available, 12 out of the 15 HIV+ group (80%) and 30 out of the 63 remaining HIV- patients (47.6%) went on to have recurrent disease (Figure 2).

An analysis of the effect of centricity and focality on the time to disease recurrence indicated that both factors had a significant effect on the rate of recurrence; multicentricity was more rapid than unicentricity ($p=0.006$; Fisher's exact test) and multifocality was more rapid than unifocality ($p<0.0001$, Fisher's exact test) (Table 1) in relation to disease recurrence and progression. A total of 31 patients presented with multifocal and multicentric disease and 23 presented with multifocal and unicentric disease. These multifocal-multicentricpatients had a significantly ($p=0.0005$) shorter time to disease recurrence (Table 1). The average time to disease recurrence in HIV+ patients was 3.2 years, compared to 5.4 years in the HIV- patients, with 73% of the HIV+ patients presenting with multifocal disease compared to only 61% of the HIV- patients.

In order to dissect the cause of the accelerated disease recurrence in HIV+ patients, CD4+ lymphyocyte counts and viral load were examined. The data showed a significant positive correlation between CD4+ lymphocyte count at diagnosis and time to recurrence (Figure 3a). By contrast, no significant relationship between viral load (at time of diagnosis or at time of disease?) and time to recurrence of VIN could be observed (Figure 3b). The slope of the line for CD4+ lymphocyte count and time to recurrence was 0.0039 years per CD4+ lymphocyte cell identified. This provides an estimate of time to disease recurrence in the HIV+ patient

180 population based on initial CD4+ lymphocyte counts, e.g. 1000 CD4+ cells predicts a 3.9 year

181 delay in disease recurrence.

182

Discussion

The data presented here shows that both focality and centricity of disease at initial diagnosis have a statistically significant effect on both interval to recurrence and final outcome for the patient diagnosed with VIN. Recurrence within 1 year was highest overall in those with multifocal/multicentric disease and also 6 patients (7%) of this cohort developing invasive forms of vulval cancer. This has been reported previously in only a small set of studies [14-18].

The majority of women presented with VIN 2/3, and the main concern with VIN 2/3 is its potential to progress to cancer of the vulva. A woman's risk of developing cancer of the vulva by the age of 75 years varies between countries, and ranges from 0.01% to 0.28% although the true rate of progression to invasive vulval cancer in women with untreated high-grade VIN is debatable, with some studies suggesting a rate as high as 9% [19]. The rates and the risk of progression in treated lesions has been reported as between 2% and 5% [2], with an increase in vulval cancer in women under the age of 50 years being increasingly documented [6, 20]. This has been linked to an increasing incidence of VIN in younger women, which has been attributed to infection with HPV, smoking or poor immunological status especially in HIV+ women [4, 14, 21]. Treatment modality did not seem to have any significant effect on outcome. This is similar to previous studies where radical vulvectomy or combination therapy had no significant effect on patient outcomes [7, 8, 22]. What is clear from previous work is that immunocompromised patients are at a higher risk of recurrent disease [23].

In this study, 17% of the patient group were HIV+, which is significantly higher when compared to the general female population of West London aged 21-86, during the diagnostic period, where 0.1% were known to be HIV+. This suggests that VIN may occur as a consequence of HIV infection, possibly through the loss of CD4+ lymphocytes or increased

viral load. The corollary of this would be that patients that have increased viral loads or were HIV+ at the time of initial presentation might have a greater susceptibility to disease recurrence. These ideas were examined and viral load did not seem to have any effect on the rate of disease recurrence, but CD4+ lymphocyte count did in our patient cohort. In fact, the data (albeit from a small sample) suggests that CD4+ count could be a good predictor of disease recurrence in HIV+ women with VIN, although these data need confirmation in a larger sample for any useful prognostic value.

Symptoms at presentation were very similar in both HIV+ and HIV- patients, with 60% presenting with a lesion alone or alongside other symptoms including pruritus and vulval pain. We noted a greater number of HIV+ patients (93%) had the more advanced form of VIN (VIN3) when compared to only 76% of the HIV- patients, suggesting that the presumably higher CD4+ lymphocyte count in the HIV- patients provides suitable immune surveillance and prevention of conversion to malignancy – I WOULD PROBABLY SAY THIS MAY HAVE PREVENTED PROGRESSION TO HIGHER GRADE DISEASE, RATHER THAN CONVERSION TO MALIGNANCY. This is supported by the observation that the majority (85%) of HIV+ patients had a synchronous or previous diagnosis of CIN/VAIN, whilst synchronous or metachronous CIN/VAIN were only diagnosed in <50% of HIV- patients. These data suggest that HIV+ patients have a greater propensity for the development of such neoplasms. Radical vulvectomy did not seem to show any improvement over any other treatment modality suggesting that a conservative approach in younger women is an acceptable treatment option.

Conclusions

The centricity and focality of VIN lesions at the time of diagnosis should be determined and the presence of both parameters act as a warning for the gynaecologist/ gynaecology

oncologist to initiate close monitoring for disease recurrence. We believe that the presence of both parameters may eventually be used to predict those women at high risk of VIN recurrence and progression, which may influence and guide treatment choices.

Immunosuppressed groups, in particular HIV+ patients, are more likely to present with multifocal and more advanced disease (VIN2/3), and as such HIV+ patients with multifocal VIN and/or known immunosuppression (demonstrated by a low CD4+ lymphocyte count) should be regarded as 'high-risk' patients and treated accordingly. Such groups may be appropriately managed in clinics with access to multi-disciplinary services, including dermatologists, whose experience with the use of imiquImod (or other treatment modalities) may change the treatment choice.

Table 1: Interval to VIN disease recurrence based on focality and centricity

Lesion type	Interval to Recurrence (Years)				Totals
	<1	2	3-5	>5	
Unifocal and unicentric	1	2	2	2	**7**
Unifocal and multicentric	14	2	0	1	**17**
Multifocal and unicentric	3	10	4	6	**23**
Multifocal and multicentric	11	10	4	6	**31**
Totals	**29**	**24**	**10**	**15**	**78**
Permutation χ^2 p-value	0.0005				

Fisher's exact test indicated that multicentric disease significantly shortened the interval to disease recurrence (p=0.0063) and multifocal disease significantly shortened the interval to disease recurrence (p<0.0001) when compared to their unicentric or unifocal counterparts. The permutation $\chi 2$ p-value for the comparison of multifocal and multicentric disease *versus* multifocal and unicentric disease is also shown.

Table 2: The effect of treatment modality on the interval to recurrence and final patient outcome in December 2017

Treatment	Interval from treatment to recurrence (years)				Totals	Final Outcome*				Totals
	≤ 1	1-2	3-5	>5		Follow up	Re-treated/EUA	Invasive	Died	
None	1	2	3	0	**6**	6	0	0	0	**6**
Observation	17	8	1	4	**30**	31	1	1	0	**33**
Laser	7	8	3	5	**23**	13	9	1	3	**26**
Diathermy ablation	3	4	2	3	**12**	6	6	0	0	**12**
Diathermy excision	0	1	1	1	**3**	0	2	0	1	**3**
Imiquimod	0	1	0	0	**1**	1	0	0	0	**1**
Radiotherapy	0	0	0	1	**1**	0	1	0	0	**1**
Referral to cancer centre	1	0	0	0	**1**	0	1	0	0	**1**
Vulvectomy	0	0	0	1	**1**	0	1	0	0	**1**
Totals	**29**	**24**	**10**	**15**	**78**	**57**	**21**	**2**	**4**	**84**
Permutation χ^2 p-value	0.14					0.12				

*Follow up means a patient with chronic VIN, but no progression of disease and so on long-term observation only; Re-treatment/EUA means a different treatment modality was applied either after evaluation under anaesthesia (EUA) or independent of re-diagnosis, invasive means VIN had progressed to vulval cancer.

References:

1. Sideri M, Jones RW, Wilkinson EJ, Preti M, Heller DS, Scurry J, et al. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. J Reprod Med. 2005 Nov;50(11):807-10. PubMed PMID: 16419625. English.

2. Jones RW. Vulval intraepithelial neoplasia: current perspectives. Eur J Gynaecol Oncol. 2001;22(6):393-402. PubMed PMID: 11874067. English.

3. van der Avoort IAMMDMS, Shirango HMD, Hoevenaars BMMD, Grefte JMMMDPD, de Hullu JAMDPD, de Wilde PCMMDPD, et al. Vulvar Squamous Cell Carcinoma is a Multifactorial Disease Following Two Separate and Independent Pathways. International Journal of Gynecological Pathology. 2006;25(1):22-9. English.

4. Ferenczy A, Coutlee F, Franco E, Hankins C. Human papillomavirus and HIV coinfection and the risk of neoplasias of the lower genital tract: a review of recent developments. CMAJ. 2003;169(5):431-4. English.

5. Bernstein SG, Kovacs BR, Townsend DE, Morrow CP. Vulvar carcinoma in situ. Obstet Gynecol. 1983 Mar;61(3):304-7. PubMed PMID: 6823372. English.

6. Jones RW, Baranyai J, Stables S. Trends in squamous cell carcinoma of the vulva: the influence of vulvar intraepithelial neoplasia. Obstet Gynecol. 1997 Sep;90(3):448-52. PubMed PMID: 9277660. English.

7. Joura EA. Epidemiology, diagnosis and treatment of vulvar intraepithelial neoplasia. Curr Opin Obstet Gynecol 2002;14(39-43).

8. Todd RW, Luesley DM. Medical management of vulvar intraepithelial neoplasia. J. 2005 Oct;9(4):206-12. PubMed PMID: 16205189. English.

9. Hillemanns P, Wang X, Staehle S, Michels W, Dannecker C. Evaluation of different treatment modalities for vulvar intraepithelial neoplasia (VIN): CO2 laser vaporization, photodynamic therapy, excision and vulvectomy. Gynecol Oncol. 2006;100:271-5.

10. Hillemanns P, Untch M, Dannecker C, Baumgartner R, Stepp H, Diebold J, et al. Photodynamic therapy of vulvar intraepithelial neoplasia using 5-aminolevulinic acid. Int J Cancer. 2000 Mar 01;85(5):649-53. PubMed PMID: 10699944. English.

11. Le T, Menard C, Hicks-Boucher W, Hopkins L, Weberpals J, Fung-Kee-Fung M. Final results of a phase 2 study using continuous 5% Imiquimod cream application in the primary treatment of high-grade vulva intraepithelial neoplasia. Gynecol Oncol. 2007 Sep;106(3):579-84. PubMed PMID: 17582474. English.

12. Mathiesen O, Buus SK, Cramers M. Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double-blinded study. Gynecol Oncol. 2007 Nov;107(2):219-22. PubMed PMID: 17655918. English.

13. Tristram A, Fiander A. Clinical responses to Cidofovir applied topically to women with high grade vulval intraepithelial neoplasia. Gynecol Oncol. 2005 Dec;99(3):652-5. PubMed PMID: 16169066. English.

14. Bradbury M, Cabrera S, Garcia-Jimenez A, Franco-Camps S, Sanchez-Iglesias JL, Diaz-Feijoo B, et al. Vulvar intraepithelial neoplasia: clinical presentation, management and outcomes in women infected with HIV. AIDS. 2016;30(6):859-68. English.

15. Nathan LM. Vulvovaginal disorders in the elderly woman. Clinical Obstetrics & Gynecology. 1996;39(4):933-45. English.

16. Rettenmaier MAM, Berman MLM, DiSaia PJM. Skinning vulvectomy for the treatment of multifocal vulvar intraepithelial neoplasia. Obstet Gynecol. 1987;69(2):247-50. English.

17. Stephenson RDDO, Denehy TRMD. Rapid spontaneous regression of acute-onset vulvar intraepithelial neoplasia 3 in young women: A case series. J Low Genit Tract Dis. 2012;16(1):56-8. English.

18. van Beurden M, ten Kate FJ, Smits HL, Berkhout RJ, de Craen AJ, van der Vange N, et al. Multifocal vulvar intraepithelial neoplasia grade III and multicentric lower genital tract neoplasia is associated with transcriptionally active human papillomavirus. Cancer. 1995 Jun 15;75(12):2879-84. PubMed PMID: 7773937. English.

19. van Seters M, Fons G, van Beurden M. Imiquimod in the treatment of multifocal vulvar intraepithelial neoplasia 2/3. Results of a pilot study. J Reprod Med. 2002 Sep;47(9):701-5. PubMed PMID: 12380448. English.

20. Joura EA, Losch A, Haider-Angeler MG, Breitenecker G, Leodolter S. Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. J Reprod Med. 2000 Aug;45(8):613-5. PubMed PMID: 10986677. English.

21. Jones RWFF, Rowan DMF, Stewart AWBD. Vulvar Intraepithelial Neoplasia: Aspects of the Natural History and Outcome in 405 Women. Obstet Gynecol. 2005;106(6):1319-26. English.

22. Hockel M, Dornhofer N. Vulvovaginal reconstruction for neoplastic disease. Lancet Oncol. 2008 Jun;9(6):559-68. PubMed PMID: 18510987. English.

23. Maniar KP, Ronnett BM, Vang R, Yemelyanova A. Coexisting high-grade vulvar intraepithelial neoplasia (VIN) and condyloma acuminatum: independent lesions due to different HPV types occurring in immunocompromised patients. Am J Surg Pathol. 2013 Jan;37(1):53-60. PubMed PMID: 23026935. English.

Figure Legends

Figure 1. The effect of HIV status on symptoms at the time of presentation, the type of lesion present and presence of co-morbidities.

Panel a shows the symptoms described by HIV- patients (upper pie chart) and those described by HIV+ patients at the time of initial presentation. The numbers under each pie chart indicate the numbers of HIV- and HIV+ patients. The percentages are values for each patient group. Panel b shows the effect of HIV status on lesion type diagnosed at initial presentation. Visual methods and histological confirmation were used to diagnose lesion type and related to previous diagnosed HIV status. Microinvasive/invasive indicate the presence of vulval cancer. Panel c shows whether diagnosis of CIN or VAIN or both were present prior to initial diagnosis of VIN or were coincidental findings on the day of initial diagnosis. Data are presented as the % of the entire patient cohort based on HIV status.

Figure 2. The effect of HIV status on recurrence of VIN at any time after treatment.

Differential diagnosis of VIN recurrence within the period January 2002 to December 2017 (as reported by the consultant histopathologist) was recorded. Data are presented as the % of the entire patient cohort.

Figure 3. The effect of viral load and CD4+ lymphocyte count on the time to VIN recurrence in HIV+ patients.

Panel a shows the effect of viral load measured by an immunoassay (IA) that simultaneously detects both antibody to human immunodeficiency virus (HIV) and HIV p24 antigen (Architect HIV Ag/Ab Combo) and confirmation using LIAISON® XL MUREX HIV Ab/Ag HT, at the time of VIN recurrence. The time to recurrence was measured as the calendar year from initial diagnosis to report of a new lesion. CD4+ lymphocyte counts were measured using

fluorescence activated cell sorting and is presented as number of CD4+ lymphocytes per 10^9 cells. Linear regression was used to calculate potential relationships between viral load (n=7) and CD4+ lymphocyte count (n=7) and time to recurrence. Data are not shown when encompassed by another symbol. Pearson correlation co-efficient and p-values were calculated using Prism version 7.00 software.

Ayakannu et al. Figure 1.

a



b



c



Ayakannu et al. Figure 2.



Ayakannu et al. Figure 3.

a


Time to Recurrence (Years)
R2=0.0105
p=0.8327
0
2
4
6
8
0
2000
4000
6000
8000
Viral load (copies/mm3 of blood)

b


Time to Recurrence (Years)
R2=0.6658
p=0.0262
0
2
4
6
8
0
200
400
600
800
1000
CD4 count